DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Zhu AX, Kang YK, Yen CJ. , et al.
REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.
J Clin Oncol. 2018. DOI: 10.1200/JCO.2018.36.15_suppl.4003
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.